Page last updated: 2024-12-07

erythronolide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID441113
CHEBI ID27977
SCHEMBL ID13684156
MeSH IDM0115430

Synonyms (15)

Synonym
(3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-14-ethyl-4,6,7,12-tetrahydroxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
eritronolide b
C06635
erythronolide b ,
CHEBI:27977
(3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-14-ethyl-4,6,7,12-tetrahydroxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
12-deoxyerythronolide a
erythronolid b
ZFBRGCCVTUPRFQ-HWRKYNCUSA-N
SCHEMBL13684156
Q27103435
(-)-erythronolide b
erythromycin lactobionate impurity n [ep impurity]
erythromycin stearate impurity n [ep impurity]
oxacyclotetradecane-2,10-dione, 14-ethyl-4,6,7,12-tetrahydroxy-3,5,7,9,11,13-hexamethyl-, (3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
erythronolide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
superpathway of erythromycin biosynthesis1842
superpathway of megalomicin A biosynthesis842
erythromycin D biosynthesis618
superpathway of erythromycin biosynthesis (without sugar biosynthesis)823

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (21.43)18.7374
1990's2 (14.29)18.2507
2000's5 (35.71)29.6817
2010's3 (21.43)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]